Sector News

Horizon is world leader in gene-editing with Sage buy

October 1, 2014
Life sciences
The UK’s Horizon Discovery is acquiring Sage Labs of the USA in a deal which it says will create “the world’s leading gene-editing and translational genomics company”.
 
The Cambridge-headquarted group is paying up to $48 million ($16 million in cash and $32 million in new shares) for Sage, described as “a world leader in the generation of advanced in vivo transgenic disease models for use in preclinical research”. It builds upon the $8 million acquisition of CombinatoRx in July and Horizon says it is now the “go-to company for the provision of integrated product, service and research solutions at all stages of translational genomics and personalised medicine research from sequence to treatment”.
 
Sage belonged to Sigma-Aldrich before a buy-out in 2013 and has 50 employees, a direct US and European sales force and 43,000 square feet state-of-the-art facilities. This will enable the scale-up of Horizon’s product and service offerings “through access to new capabilities, capacity and access to new markets”.
 
David Smoller, Sage chief executive who will now become Horizon’s chief business officer, said the new firm “is now the destination for researchers and scientists worldwide to find both in vivo and in vitro solutions to their biological questions”.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend